Your browser doesn't support javascript.
loading
Case Report: Long-term metabolic response of metastatic uveal melanoma to pembrolizumab on FDG-PET/CT despite a serial pseudoprogressions phenomenon.
Amrane, Karim; Le Meur, Coline; Thuillier, Philippe; Dzuko Kamga, Jacques; Alemany, Pierre; Chauvelot, Frederic; Niel, Clémence; Bellange, Alex; Abgral, Ronan.
Afiliação
  • Amrane K; Department of Oncology, Centre Hospitalier des Pays de Morlaix, Morlaix, France.
  • Le Meur C; Inserm, UMR1227, Lymphocytes B et Autoimmunité, Univ Brest, Inserm, LabEx Immunotherapy-Graft-Oncology (IGO), Brest, France.
  • Thuillier P; Department of Radiotherapy, University Hospital of Brest, Brest, France.
  • Dzuko Kamga J; Inserm, UMR1227, Lymphocytes B et Autoimmunité, Univ Brest, Inserm, LabEx Immunotherapy-Graft-Oncology (IGO), Brest, France.
  • Alemany P; Department of Endocrinology, University Hospital of Brest, Brest, France.
  • Chauvelot F; Department of Nuclear Medicine, University Hospital of Brest, Brest, France.
  • Niel C; Department of Pathology, Ouestpathology Brest, Brest, France.
  • Bellange A; Department of Onco-pharmacy, Centre Hospitalier des Pays de Morlaix, Morlaix, France.
  • Abgral R; Department of Oncology, Centre Hospitalier des Pays de Morlaix, Morlaix, France.
Front Immunol ; 14: 1243208, 2023.
Article em En | MEDLINE | ID: mdl-38111583
ABSTRACT
Uveal melanoma (UV) is a rare and aggressive melanoma with poor 1-year survival. up to 50% of UV patients develop metastases, mainly to the liver. Here, the authors present a 2-deoxy-2-[18F] fluoro-D-glucose positron emission tomography (18F-FDG-PET) study of a very rare case of secondarily metastatic UV in an 81-year-old Caucasian with a dramatic response to pembrolizumab associated with serial pseudogression. 18F-FDG-PET associated with clinical status and peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) were performed to guide therapeutic strategy due to an atypical pseudoprogression phenomenon.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Melanoma Limite: Aged80 / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Melanoma Limite: Aged80 / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article